C Ray Therapeutics Highlights Expanding Role in Radiopharmaceutical Development Services

A LinkedIn post from C Ray Therapeutics discusses trends observed at AACR 2026 in radiopharmaceutical R&D, highlighting a notable shift toward alpha emitters such as Ac-225 and Pb-212, as well as a broadening range of oncology targets and ligand formats. The post points to an increasingly diversified pipeline, with multiple programs advancing into early clinical stages across indications and platforms.

According to the post, interim data for several agents, including alpha and lutetium-177 based candidates, suggest growing clinical momentum in radiotheranostics, with reported response rates and trial initiations underscoring rising investment in the modality. This environment could expand demand for specialized isotope production, clinical supply, and CRO services as more programs progress beyond preclinical proof-of-concept.

The company’s LinkedIn post highlights that C Ray Therapeutics was involved in multiple featured programs, including Ac-225–RAX104 and Cu-64–RAX301 from RadAlliance Therapeutics, for which it provided clinical supply and investigator-initiated trial CRO services. Cu-64–RAX301 is described as leveraging C Ray’s in-house Cu-64 production platform, which the post indicates can produce batches above 2 Ci at EOB, suggesting potentially scalable isotope manufacturing capacity.

The post also notes C Ray’s role in process development and technology transfer for Lu-177–PSMA-3D1015, a collaboration between 3D Medicines and Jiangnan University Hospital, after which hospital-based supply takes over. For investors, these activities may indicate a service-centric business model positioned along the radiopharmaceutical value chain, with exposure to multiple partners’ pipelines rather than single-asset risk.

As shared in the post, C Ray plans to be present at SNMMI 2026 in Los Angeles, with an emphasis on discussions around isotope supply and clinical manufacturing. While commercial terms and revenue contributions are not disclosed, visible participation in high-profile scientific meetings and association with advancing clinical programs could enhance the company’s industry visibility and support future business development opportunities.